Portfolio concentration
As of March 31, 2026 · N-PORT
Holdings
41
Top-10 weight
46.20%
Effective holdings
?
The number of equal-weight positions that would produce this portfolio's concentration (1 ÷ Herfindahl index). A 500-stock fund dominated by a few mega-caps might have only ~100 effective holdings.
27
Crowding
?
The value-weighted average number of funds that also own this fund's positions. High = consensus/crowded picks; low = holdings few other funds own.
998.6
Holdings
As of March 31, 2026 · N-PORT| # | Security | Ticker | Shares | Value | % of fund |
|---|---|---|---|---|---|
| 1 | LILLY ELI and CO | — | 13,000 | $11.96M | 9.95% |
| 2 | ASTRAZENECA PLC | — | 31,000 | $6.11M | 5.09% |
| 3 | JOHNSON&JOHNSON | — | 22,500 | $5.50M | 4.58% |
| 4 | THERMO FISHER SCIENTIFIC INC | — | 10,400 | $5.11M | 4.25% |
| 5 | METTLER-TOLEDO INTL INC | — | 3,800 | $4.79M | 3.99% |
| 6 | GILEAD SCIENCES INC | — | 30,000 | $4.18M | 3.48% |
| 7 | TEVA PHARMACEUTICAL IND ADR | — | 130,000 | $3.92M | 3.26% |
| 8 | INTUITIVE SURGICAL INC | — | 8,400 | $3.87M | 3.22% |
| 9 | ARGENX SE SPONSORED ADR | — | 5,200 | $3.80M | 3.16% |
| 10 | ROIVANT SCIENCES LTD | — | 125,000 | $3.46M | 2.88% |
| 11 | ELANCO ANIMAL HEALTH INC | — | 142,500 | $3.41M | 2.84% |
| 12 | IONIS PHARMACEUTICALS INC | — | 45,000 | $3.38M | 2.81% |
| 13 | RADNET INC | — | 60,000 | $3.35M | 2.79% |
| 14 | VERTEX PHARMACEUTICALS INC | — | 7,500 | $3.35M | 2.79% |
| 15 | INSMED INC | — | 20,000 | $3.27M | 2.72% |
| 16 | MERCK & CO | — | 25,000 | $3.01M | 2.50% |
| 17 | GUARDANT HEALTH INC | — | 32,000 | $2.96M | 2.46% |
| 18 | NATERA INC | — | 14,700 | $2.94M | 2.45% |
| 19 | MADRIGAL PHARMACEUTICALS INC | — | 5,300 | $2.77M | 2.31% |
| 20 | EDWARDS LIFESCIENCES CORP | — | 33,300 | $2.67M | 2.22% |
| 21 | IDEXX LABS INC | — | 4,700 | $2.64M | 2.20% |
| 22 | WELLTOWER INC | — | 13,000 | $2.57M | 2.14% |
| 23 | BILLIONTOONE INC | — | 27,000 | $2.13M | 1.77% |
| 24 | TERNS PHARMACEUTICALS INC | — | 35,000 | $1.85M | 1.54% |
| 25 | STRYKER CORP | — | 5,500 | $1.81M | 1.50% |
| 26 | ABBVIE INC | — | 8,000 | $1.74M | 1.45% |
| 27 | ARCUTIS BIOTHERAPEUTICS INC | — | 73,000 | $1.72M | 1.43% |
| 28 | INSULET CORP | — | 8,000 | $1.68M | 1.40% |
| 29 | KYMERA THERAPEUTICS INC | — | 20,000 | $1.67M | 1.39% |
| 30 | PROTAGONIST THERAPEUTICS INC | — | 15,000 | $1.58M | 1.32% |
| 31 | CYTOKINETICS INC | — | 23,000 | $1.52M | 1.26% |
| 32 | XENON PHARMACEUTICALS INC | — | 25,000 | $1.45M | 1.21% |
| 33 | Ascendis Pharma A/S | — | 5,600 | $1.28M | 1.07% |
| 34 | APOGEE THERAPEUTICS INC | — | 15,000 | $1.26M | 1.05% |
| 35 | HEARTFLOW INC | — | 48,848 | $1.19M | 0.99% |
| 36 | REPLIGEN CORP | — | 9,000 | $1.06M | 0.88% |
| 37 | DEXCOM INC | — | 16,000 | $1.00M | 0.84% |
| 38 | VERADERMICS INC | — | 10,000 | $631.50K | 0.53% |
| 39 | MEDLINE INC-A | — | 14,000 | $623.00K | 0.52% |
| 40 | Abivax SA SPONSORED ADS | ABVX US | 5,500 | $612.42K | 0.51% |
| 41 | REVOLUTION MEDICINES INC | — | 2,500 | $243.12K | 0.20% |
Machine-readable: JSON · Markdown. Programmatic access via the agent surface.